The growing importance of incorporating US payers into biotechnology drug development decision-making

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.17, Iss.2, 2011-05, pp. : 151-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The state of the US biotechnology industry

By Bullock W.O. Dibner M.D.

Trends in Biotechnology, Vol. 13, Iss. 11, 1995-11 ,pp. : 463-467

Elsevier

Access to resources Recommend Favorite

Revitalizing portfolio decision-making at Merck Serono S.A. – Geneva

By Aurentz Vincent Kirschbaum Bernhard Thunecke Markus

Journal of Commercial Biotechnology, Vol. 17, Iss. 1, 2011-02 ,pp. : 24-36

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Ethiopia: Biotechnology for development

By Sbhatu Desta Berhe

Journal of Commercial Biotechnology, Vol. 16, Iss. 1, 2010-01 ,pp. : 53-71

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Corporate development in biotechnology in 2005

By Williams Alan

Journal of Commercial Biotechnology, Vol. 11, Iss. 3, 2005-04 ,pp. : 239-248

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Development of Cuban biotechnology

By Mola E L

Journal of Commercial Biotechnology, Vol. 9, Iss. 2, 2003-01 ,pp. : 147-152

Palgrave Macmillan Ltd

Access to resources Recommend Favorite